Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to fab 2 fragments

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Latus, Joerg ^a   Klein, Reinhild ^b   Koetter, Ina ^a   Schwab, Matthias ^c   Fritz, Peter ^d   Kimmel, Martin ^a   Alscher, M Dominik ^a   Braun, Niko ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Institute of Digital Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CROSS REACTING ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; RITUXIMAB;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOMATOSIS; HUMAN; HUMAN CELL; MALE; MICROSCOPIC POLYANGIITIS; PROTEIN FUNCTION; SEROLOGY;

ACUTE DISEASE; ADULT; AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHOLESTASIS, INTRAHEPATIC; CROSS REACTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MALE; MICE; MIDDLE AGED; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84892942432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078856     Document Type: Article

References (23)

1. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, et al. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94: 2217-2224. (Pubitemid 29467667)
2. Del Prete CJ, Cohen NS (2010) A case of rituximab-induced hepatitis. Cancer Biother Radiopharm 25: 747-748.
3. Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, et al. (2005) Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 80: 43-45. (Pubitemid 41254267)
4. Ng PC, Lee KK, Lo AF, Li CK, Fok TF (2003) Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child 88: 337-339. (Pubitemid 36398976)
5. Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, et al. (2002) Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood 100: 1104-1105. (Pubitemid 34832655)
6. Ng HJ, Lim LC (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 80: 549-552. (Pubitemid 32910401)
7. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345: 1000.
8. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, et al. (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69: 1612-1617.
9. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806. (Pubitemid 44497758)
10. Fleischmann RM (2009) Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 38: 265-280.
11. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, et al. (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term followup. JAMA 305: 1460-1468.
12. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, et al. (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66: 921-926. (Pubitemid 46999794)
13. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, et al. (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68: 1739-1745.
14. Shankar G, Shores E, Wagner C, Mire-Sluis A (2006) Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24: 274-280. (Pubitemid 43853075)
15. Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20: 431-435.
16. Pichler WJ, Tilch J (2004) The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59: 809-820. (Pubitemid 39005820)
17. Grasland A, Sterpu R, Boussoukaya S, Mahe I (2011) Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol.
18. Osterland CK, Harboe M, Kunkel HG (1963) Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang 8: 133-152.
19. Williams RC, Kunkel HG (1965) Observations on antigamma globulin factors in human sera and antibodies against autologous gamma globulins produced in rabbits. Ann N Y Acad Sci 124: 860-864.
20. Persselin JE, Stevens RH (1985) Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest 76: 723-730. (Pubitemid 15023128)
21. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34: 19-22.
22. Johansson AG, Sundqvist T, Skogh T (2000) IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes. Int Arch Allergy Immunol 121: 329-336. (Pubitemid 30229646)
23. Lovdal T, Andersen E, Brech A, Berg T (2000) Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 113 (Pt 18): 3255-3266.